Abstract:Objective: Diagnosis and treatment of gastroenteropancreatic high-grade neuroendocrine neoplasms (GEP-HG-NENs), particularly G3 well-differentiated neuroendocrine tumours (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) relies on histopathological morphology, immunohistochemistry, and molecular biological markers, which are lacking especially in cases with ambiguous histomorphology. In this study to contribute to the development of more targeted treatment strategies, we examined various immunohistochemical and molecular biological markers and their association with clinicopathological features in GEP-HG-NENs. Methods: We included 38 patients with GEP-HG-NENs in this study, with their retrospective follow-up data. The expression of tumour protein p53 (TP53), RB transcriptional corepressor 1 (RB1), somatostatin receptor 2 (SSTR2), clusterin (CLU), and marker of proliferation Ki-67 (MKI67) was immunohistochemically analysed. KRAS proto-oncogene, GTPase ( KRAS ) and B-Raf proto-oncogene, serine/threonine kinase ( BRAF ) V600E expression was evaluated using quantitative real-time polymerase chain reaction (qRT-PCR). The relationships between immunohistochemical and molecular biological markers and clinicopathological characteristics were examined using a Cox risk regression model, receiver operating characteristic (ROC) curve, and Kaplan–Meier survival analyses. Results: SSTR2, RB, TP53, and CLU expression differed between NET G3 and NECs, with variations among the NET G3 and small- and large-cell NEC (SCNEC and LCNEC, respectively) groups ( p < 0.05). The median MKI67 proliferative index was approximately 40% and 70% in G3 NETs and NECs, respectively. The NET G3 group exhibited a median survival of 25 months, indicating a relatively better prognosis than that of the NECs group (median survival, 11 months). Both Kaplan–Meier survival analysis and the Cox risk regression model indicated a statistical correlation among treatment methods, CLU expression, and prognosis ( p < 0.05). The BRAF V600E mutation rate was 32.4% in G3 NETs and SCNEC, demonstrating a significant difference between both types ( p = 0.0086). Furthermore, ROC curve analysis highlighted the diagnostic significance of the positive expression of the immunohistochemical markers CLU, SSTR2, and RB in identifying NET G3. Conclusion: To guide more suitable treatment strategies, it is essential to develop and apply valuable and more targeted immunohistochemical and molecular pathological markers for a comprehensive analysis.

Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.

Machine Learning Methods Based on CT Features Differentiate G1/G2 from G3 Pancreatic Neuroendocrine Tumors.

How Reliable is the Ki-67 Cytological Index in Grading Pancreatic Neuroendocrine Tumors? A Meta-Analysis

Clinical Significance of the Preoperative Main Pancreatic Duct Dilation and Neutrophil-to-lymphocyte Ratio in Pancreatic Neuroendocrine Tumors (pnets) of the Head after Curative Resection

Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.

Clinical Relevance of Different WHO Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology

[Accurate Grading of Pancreatic Neuroendocrine Tumors with Ki-67 Index in Fine-Needle Aspiration Specimens: a Comparative Cytologic and Histologic Study].

Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.

Long-term outcomes of World Health Organization G 3 pancreatic neuroendocrine neoplasms : a retrospective study in combination of morphological and proliferative analysis

Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors.

The Assessment of Ki-67 for Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasm Patients: a Systematic Review and Meta-Analysis

World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution

Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors

Consensus on the Clinical Diagnosis and Treatment of Grade 3 Pancreatic Neuroendocrine Tumors

Surgical Outcomes and Prognostic Factors of G3 Pancreatic Neuroendocrine Carcinomas: A Consecutive Analysis Based on Previous Study Results

A CT-based diagnostic nomogram and survival analysis for differentiating grade 3 pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas

Clinicopathological correlations in 38 cases of gastroenteropancreatic high-grade neuroendocrine neoplasms

Survivals of Patients with Pancreatic Neuroendocrine Carcinomas an In-Depth Analysis by the American Joint Committee on Cancer 8th Tumor-Node-metastasis Staging Manual

Clinical Outcomes and Prognostic Factors of Resected Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience in China.

Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.

Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors: A Comprehensive Analysis of 254 Consecutive Patients From a Large Chinese Institution.